logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US RE50490 B1

PDFFull Text
Date of Patent:
Jul. 15, 2025

Filed:

Nov. 10, 2022

Substituted quinazoline compounds and methods of use thereof

Applicant:

Araxes Pharma Llc, San Diego, CA (US);

Inventors:

Liansheng Li, San Diego, CA (US);

Jun Feng, San Diego, CA (US);

Yun Oliver Long, San Diego, CA (US);

Yuan Liu, San Diego, CA (US);

Tao Wu, Carlsbad, CA (US);

Pingda Ren, San Diego, CA (US);

Yi Liu, San Diego, CA (US);

Assignee:

Araxes Pharma LLC, San Diego, CA (US);

Attorney:

Seed IP Law Group LLP

Primary Examiner:

Alan D Diamond

Int. Cl.
CPC ...
C07D 239/74 (2006.01); C07D 239/94 (2006.01); C07D 239/95 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 417/04 (2006.01); C07D 471/08 (2006.01); C07D 487/10 (2006.01); C07D 491/10 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07D 239/74 (2013.01); C07D 239/94 (2013.01); C07D 239/95 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07D 471/08 (2013.01); C07D 487/10 (2013.01); C07D 491/10 (2013.01); C07F 9/65583 (2013.01);
Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R, R, R, R, R, R, R, R, R, R, A, B, G, G, L, L, m, m, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Find Patent Forward Citations

Loading…